SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced positive phase III overall survival data for its…

GSK plc · 6-K filed Jul 10, 2026 at 08:13 ET

At the news

BULLISHIMPACT 5/10

6-K filed Jul 10, 2026 at 08:13 ET

GSK announced positive phase III overall survival data for its B7-H3-targeted ADC risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer from the Chinese ARTEMIS-008 trial. This is the first positive phase III OS data for any B7-H3-targeted ADC, de-risking GSK's pipeline and supporting its global development program. The data is from a China-only trial by licensor Hansoh Pharma; GSK's own global phase III EMBOLD SCLC-301 results are expected next year.

  • ARTEMIS-008 phase III trial met primary endpoint of overall survival in advanced/relapsed SCLC, with statistically significant and clinically meaningful improvement vs topotecan.
  • First positive phase III overall survival data for a B7-H3-targeted ADC in any tumour type.
  • GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan.
  • Global phase III EMBOLD SCLC-301 trial in relapsed ES-SCLC with pivotal data expected next year.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access